J. Goldman & CO LP Protagonist Therapeutics, Inc Transaction History

J. Goldman & CO LP

$3.35 Billion
Q3 2025

A detailed history of J. Goldman & CO LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, J. Goldman & CO LP holds 18,068 shares of PTGX stock, worth $1.53 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

18,068

Previous 35,828 49.57%

Holding current value

$1.53 Million

Previous $1.98 Million 39.39%

% of portfolio

0.04%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$49.7 - $67.42 $882,672 - $1.2 Million	-17,760 Reduced 49.57%	18,068 $1.2 Million
Q2 2025 Aug 14, 2025	SELL	$40.89 - $56.37 $1.2 Million - $1.66 Million	-29,416 Reduced 45.09%	35,828 $1.98 Million
Q1 2025 May 15, 2025	BUY	$35.09 - $59.76 $2.29 Million - $3.9 Million	65,244 New	65,244 $3.16 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $25.52 $578,023 - $2.09 Million	-81,873 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $1.14 Million - $1.76 Million	-48,644 Reduced 37.27%	81,873 $1.94 Million

Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $2.3 Million - $4.84 Million	130,517 New	130,517 $4.46 Million
Q3 2021 Nov 15, 2021	SELL	$12.95 - $49.69 $258,818 - $993,104	-19,986 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $756,693 - $1.33 Million	-29,593 Reduced 59.69%	19,986 $897,000
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $213,746 - $350,063	11,238 Added 29.31%	49,579 $1.28 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $279,661 - $380,091	15,125 Added 65.15%	38,341 $773,000
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $397,112 - $585,603	-26,143 Reduced 52.97%	23,216 $454,000
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $305,532 - $929,923	49,359 New	49,359 $872,000

Others Institutions Holding PTGX

# of Institutions

294

Shares Held

66.9M

Call Options Held

139K

Put Options Held

40.7K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $4.15B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Account